Get to know our clinical trials
Clinical trial of Xmab24306 in monotherapy and in combination with Atezolizumab in patients with locally advanced or metastatic solid tumors.
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE XMAB24306 AT DIFFERENT DOSES TO DETERMINE IF IT IS SAFE AND TO LEARN HOW YOUR BODY PROCESSES THE DRUG.
Codirector
Immunology and Immunotherapy Department
Navarre headquarters
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE IA/IB, OPEN-LABEL, MULTICENTER, GLOBAL, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF XMAB24306 IN MONOTHERAPY AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS. IMMUNOTHERAPY
- Code EudraCT: 2019-003986-16
- Protocol number: GO41596
- Promoter: Genentech, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.